AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation
